NasdaqCM:VRCAPharmaceuticals
Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability
Verrica Pharmaceuticals (VRCA) just closed out FY 2025 with Q4 revenue of US$5.1 million and a basic EPS loss of US$0.57, alongside trailing 12 month revenue of US$35.6 million and a basic EPS loss of US$1.68. Over the past few quarters, the company has seen revenue move from US$3.4 million in Q1 2025 to US$12.7 million in Q2 and US$14.3 million in Q3, while quarterly basic EPS has ranged from a loss of US$1.03 in Q1 to a small profit of US$0.02 in Q2 and a near breakeven loss of US$0.03 in...